Science & Platform
Our proprietary directed evolution platform converts native immune system proteins into differentiated, multi-targeted therapeutics potentially capable of modulating the human immune system and significantly improving outcomes in patients with serious diseases. Our scientists use of directed evolution, an iterative protein engineering process, to modify native proteins for a desired therapeutic function.
Transforming Native Immune System Proteins
We have successfully applied our scientific platform to multiple costimulatory and immunosuppressive proteins with potential applications in cancer and autoimmune and inflammatory diseases. Our platform is able to improve upon the activity of these native IgSF or TNFSF/TNFRSF proteins, transforming them into therapeutic candidates with an enhanced ability to bind multiple targets.
Highly Flexible Formatting
Because of our platform’s unique attributes, the multispecific proteins we create are highly flexible in regard to final formatting, including Fc fusion, cell therapy, monoclonal antibody, or other. In many cases, a single directed evolution campaign can result in multiple proteins suitable for use in several final formats.